#USA #New York #Securities Fraud #Pomerantz LLP #Omeros Corporation

Pomerantz Law Firm Investigates Omeros Corporation

Pomerantz LLP, a prestigious law firm known for its success in handling securities litigation, has begun an investigation into allegations of securities fraud on behalf of investors of Omeros Corporation (NASDAQ: OMER). This investigation arises from a series of troubling events regarding Omeros' recently submitted marketing authorization application (MAA) for its drug, narsoplimab.

Overview of the Investigation

The central concern of Pomerantz is whether Omeros, along with its executives and directors, has participated in any unlawful business practices that could be detrimental to investors. The firm encourages affected investors to reach out to them directly.

On June 26, 2026, Omeros announced in a press release that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had delivered a negative opinion on its MAA for narsoplimab, intended for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The unfortunate news led to a significant drop in Omeros' stock, falling $2.05 or 19.12% to close at $8.67 per share.

Following this, on October 16, 2026, Omeros issued another press release reiterating the negative stance from the CHMP after a thorough re-examination of the application. This announcement was accompanied by another sharp decline in stock price, which dropped by $2.59, or 13.78%, finishing at $16.20 per share.

Legal Implications for Omeros

The investigation led by Pomerantz LLP reinforces the larger legal framework surrounding corporate accountability when it comes to pharmaceutical development and stock performance. Investors are not only concerned with the initial drug approvals but also the subsequent corporate communications, particularly when those communications impact stock prices.

Pomerantz, established over 85 years ago and led by founder Abraham L. Pomerantz, has a long-standing reputation for fighting for investors' rights in cases of securities fraud and corporate misconduct. This investigation aims to hold Omeros accountable if evidence suggests that misrepresentation or negligence has misled investors.

Significance for Investors

This case highlights the critical need for transparency in communications from pharmaceutical companies, especially during times of significant announcements such as drug approvals or rejections. For investors, the implications are profound, with trust in a company's future directly affecting stock market performance.

As the investigation unfolds, it will be essential for Omeros to provide clear and truthful information to its investors to restore confidence and protect its market integrity. Investors affected by the recent drops in stock prices are strongly advised to keep in close contact with legal experts and stay informed about developments in this case.

If you believe you have been impacted by Omeros' potential misconduct, reach out to Danielle Peyton at Pomerantz LLP for further guidance. The firm is dedicated to supporting victims of securities fraud and ensuring they receive the necessary legal backing to address their concerns.

For more information, visit Pomerantz LLP's website. They continue to uphold their commitment to fight for the rights of investors and seek justice in securities litigation matters.